Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

FDA grants accelerated approval for Astellas, Seattle Genetics' bladder cancer drug

(Reuters) - U.S. Food and Drug Administration said on Wednesday it approved Astellas Pharma Inc and Seattle Genetics’ experimental drug to treat advanced bladder cancer, about three months ahead of schedule.

Shares of Seattle Genetics were up 6% at $119.05 after the bell.

The drug, Padcev, is approved in the United States for patients with advanced or metastatic urothelial cancer, the companies said.

The drug will treat patients with advanced bladder cancer whose disease has progressed even after treatment with immunotherapy and chemotherapy.

The American Cancer Society estimates 17,670 people will die from bladder cancer in the United States this year.

The continued approval of the drug may depend upon verification of clinical benefit in confirmatory trials, the companies said, adding that a late-stage study is underway.

The FDA’s accelerated approval program allows conditional approval of a medicine that fills an unmet medical need for a serious condition.

DECEMBER 19, 2019


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies